The Cooper Companies, Inc. $COO Stock: New Mexico Educational Retirement Board Grows Position

New Mexico Educational Retirement Board grew its position in The Cooper Companies, Inc. (NASDAQ:COO) by 98.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 19,238 shares of the medical device company’s stock after acquiring an additional 9,538 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Cooper Companies were worth $1,088,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Avalon Trust Co acquired a new position in Cooper Companies in the 2nd quarter valued at $25,000. Elevation Wealth Partners LLC lifted its holdings in Cooper Companies by 1,136.4% in the 2nd quarter. Elevation Wealth Partners LLC now owns 408 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 375 shares in the last quarter. Continuum Advisory LLC acquired a new stake in Cooper Companies during the 2nd quarter worth $30,000. Jacobi Capital Management LLC acquired a new stake in Cooper Companies during the 3rd quarter worth $25,000. Finally, J.Safra Asset Management Corp acquired a new stake in Cooper Companies during the 2nd quarter worth $32,000. 24.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

COO has been the subject of a number of recent research reports. Barclays upgraded shares of Cooper Companies to a “hold” rating in a research report on Wednesday, October 7th. Mizuho set a $75.00 price target on shares of Cooper Companies and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Bank of America lowered shares of Cooper Companies from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $80.00 to $65.00 in a research report on Thursday, September 10th. UBS Group dropped their price objective on shares of Cooper Companies from $75.00 to $66.00 and set a “neutral” rating for the company in a research note on Thursday, September 10th. Finally, Stifel Nicolaus set a $70.00 price objective on shares of Cooper Companies and gave the company a “buy” rating in a report on Thursday, September 10th. Four investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $68.60.

Cooper Companies Stock Performance

NASDAQ COO opened at $62.93 on Thursday. The stock’s fifty day moving average is $58.80 and its two-hundred day moving average is $68.33. The firm has a market capitalization of $11.97 billion, a P/E ratio of 21.48, a price-to-earnings-growth ratio of 2.50 and a beta of 0.83. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.73 and a current ratio of 1.22. The Cooper Companies, Inc. has a fifty-two week low of $51.01 and a fifty-two week high of $89.83.

Cooper Companies (NASDAQ:COO) last issued its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.03. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.10 billion. During the same period in the prior year, the business earned $0.49 EPS. The firm’s quarterly revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. On average, research analysts anticipate that The Cooper Companies, Inc. will post 4.53 earnings per share for the current year.

Cooper Companies announced that its board has authorized a stock repurchase plan on Wednesday, September 9th that permits the company to repurchase $3 billion in outstanding shares. This repurchase authorization permits the medical device company to reacquire up to 22.7% of its stock through open market purchases. Share repurchase plans are usually an indication that the company’s board believes its stock is undervalued.

Insider Activity at Cooper Companies

In other news, Director Walter Rosebrough, Jr. acquired 3,000 shares of the company’s stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average price of $54.29 per share, with a total value of $162,870.00. Following the completion of the acquisition, the director owned 20,000 shares of the company’s stock, valued at $1,085,800. This trade represents a 17.65% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Lawrence Kurzius acquired 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 16th. The shares were purchased at an average price of $54.93 per share, with a total value of $549,300.00. Following the completion of the transaction, the director owned 31,099 shares of the company’s stock, valued at $1,708,268.07. The trade was a 47.40% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders bought 34,701 shares of company stock valued at $1,880,039. 2.08% of the stock is owned by company insiders.

About Cooper Companies

CooperCompanies is a global medical device company focused on vision care and women’s health. It serves customers in markets around the world through two primary businesses: CooperVision and CooperSurgical. CooperVision develops and sells contact lenses, including products for daily wear, astigmatism, presbyopia and myopia management. Its offerings include lenses made from silicone hydrogel and other materials, as well as specialty lens options. CooperSurgical provides products and services for women’s health and fertility care.